Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
Published version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Purpose: The survival of patients with hepatocellular carcinoma (HCC) recurrence after curative resection is usually poor. We sought to evaluate the safety and efficacy of adjuvant transarterial chemoembolization (TACE) in HBV-related HCC patients with an intermediate (a single tumor larger than 5 cm without microvascular invasion) or high risk (a single tumor with microvascular invasion, or two or three tumors) of recurrence. Experimental Design: In this randomized phase 3 trial, 280 eligible patients were assigned to adjuvant TACE (n = 140) or no adjuvant treatment (control; n = 140) groups. The primary endpoint was recurrence-free survival (RFS); secondary endpoints included overall survival (OS) and safety. Multivariable Cox-proportional hazards model was used to determine the independent impact of TACE on patients' outcomes. Results: Patients who received adjuvant TACE had a significantly longer RFS than those in the control group [56.0% vs. 42.1%, P = 0.01; HR, 0.68; 95% confidence interval (CI), 0.49–0.93]. Patients in the adjuvant TACE group had 7.8% higher 3-year OS rate than the control group (85.2% vs. 77.4%; P = 0.04; HR, 0.59; 95% CI, 0.36–0.97). The impact of adjuvant TACE on RFS and OS remained significant after controlling for other known prognostic factors (HR, 0.67; P = 0.01 for RFS; and HR, 0.59; P = 0.04 for OS). There was no grade 3 or 4 toxicity after adjuvant TACE. Conclusions: For patients with HBV-related HCC who had an intermediate or high risk of recurrence after curative hepatectomy, our study showed adjuvant TACE significantly reduced tumor recurrence, improved RFS and OS, and the procedure was well tolerated. Clin Cancer Res; 24(9); 2074–81. ©2018 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, RCTs conducted in China have reported clinical benefits with (neo)adjuvant therapies.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [93]
Citations
Cites
Dindo, D., Demartines, N., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133083.54934.ae · Cited by 31,378
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Power and sample size calculations
Dupont, W. D., & Plummer, W. D. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90005-m · Cited by 2,092
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120 · cited 1×
“Although the SHARP andORIENTAL trials have shownpromising effectiveness with sorafenib in treatment of advanced HCC, the STORM study failed to show any effectiveness in the adjuvant setting for patients after surgical resection or who had complete radiological response to ablation (20).”
MethodRecurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis
Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M., & Roayaie, S. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000710 · Cited by 903 · cited 1×
“However, high tumor recurrence rates after curative liver resection (60%–70% in the first 5 years of surgery) continues to be amajor cause of death inHCC (3, 4).”
Backgroundde Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
Lee, J. H., Lee, J.-H., Lim, Y.-S., Yeon, J. E., Song, T.-J., Yu, S. J., Gwak, G.-Y., Kim, K. M., Kim, Y. J., Lee, J. W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.055 · Cited by 503
Cited by
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Self-citationXie, D.-Y., Ren, Z.-G., Zhou, J., Fan, J., & Gao, Q. (2020) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-20-480 · Cited by 479
Self-citationGuidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Xie, D., Shi, J., Zhou, J., Fan, J., & Gao, Q. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0402 · Cited by 177
“cTACE is also recommended in the adjuvant setting for patients with high recurrent risks including multiple lesions, evidence of tumor thrombus or tumor diameter >5 cm.(48) In real-life practices, the combination of TACE with other locoregional treatment or systemic therapy is emphasized.”
Self-citation
Metadata
- Authors
- Wang, Z., Ren, Z., Chen, Y., Hu, J., Yang, G., Yu, L., Yang, X., Huang, A., Zhang, X., Zhou, S., Sun, H., Wang, Y., Ge, N., Xu, X., Tang, Z., Lau, W., Fan, J., Wang, J., & Zhou, J.
- Affiliations
- Fudan University (CN)
- 1Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
- Chinese University of Hong Kong (HK)
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2018-04-30
- Volume
- 24
- Issue
- 9
- Pages
- 2074-2081
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2787942673
- Cited by
- 318
- References
- 30
- Citations by year
- 2026: 23 · 2025: 46 · 2024: 43 · 2023: 66 · 2022: 37 · 2021: 53 · 2020: 27 · 2019: 17 · 2018: 6
- FWCI
- 16.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science and Technology Major Project (2018ZX10723204)
- National Key R&D Program of China (2016YFC0902400)
- National Natural Science Foundation of China (81772578)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- hepatocellular carcinoma, HBV-related liver cancer, hepatectomy, tumor recurrence, recurrence-free survival, overall survival, microvascular invasion
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Hepatitis B, Hepatitis B virus, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Chemoembolization, Therapeutic, Treatment Outcome, Kaplan-Meier Estimate, Young Adult, Chemoradiotherapy, Adjuvant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2899
- The paper
- Wang, Z., Ren, Z., Chen, Y., Hu, J., Yang, G., Yu, L., Yang, X., Huang, A., Zhang, X., Zhou, S., Sun, H., Wang, Y., Ge, N., Xu, X., Tang, Z., Lau, W., Fan, J., Wang, J., & Zhou, J. (2018). Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2899
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.